

In response to the First Office Action, please amend the above-referenced application as follows:

In the Claims:

Please amend claims 13, 20, 23, 24, 46 and 60 as follows:

B¹

13. (Amended) A composition comprising functional dendritic antigen presenting cells derived from monocytes which have been incubated following their treatment by at least one of: (1) exposure to physical perturbation, (2) irradiation in the presence of a photoactivatable agent, said photoactivatable agent being capable of forming photoadducts with cellular components, or (3) treatment with a DNA binding agent.

B²

20. (Amended) The composition of claim 14, further comprising at least one of GM-CSF or IL-4.

23. (Amended) The composition of claim 22, wherein the disease effector agent is selected from the group consisting of disease-causing cells and microbes.

B³

24. (Amended) A packaged preparation comprising:
a composition including functional dendritic antigen presenting cells derived from monocytes which have been incubated following their treatment by at least one of exposure to physical perturbation, irradiation in the presence of a photoactivatable agent, said photoactivatable agent being capable of forming photoadducts with cellular components, and treatment with a DNA binding agent; and
a container which does not leach substantial amounts of plasticizer and which is sufficiently porous to permit exchange of gases for storing the composition.

B⁴

46. (Amended) A composition of co-incubated populations comprising:
a first population including disease effector agents which express at least one disease associated antigen; and

B⁴

a second population including functional dendritic antigen presenting cells derived from monocytes which have been treated by at least one of: (1) exposure to physical perturbation, (2) irradiation in the presence of a photoactivatable agent, said photactivatable agent being capable of forming photoadducts with cellular components, or (3) treatment with a DNA binding agent.

B⁵

60. (Amended) A packaged composition of co-incubated populations comprising:
a first population including disease effector agents which express at least one disease associated antigen;
a second population including functional dendritic antigen presenting cells derived from monocytes which have been treated by at least one of: (1) exposure to physical perturbation, (2) irradiation in the presence of a photoactivatable agent, said photoactivatable agent being capable of forming photoadducts with cellular components, or (3) treatment with a DNA binding agent; and
a container which does not leach substantial amounts of plasticizer and which is sufficiently porous to permit exchange of gases for storing the composition.

B⁶

64. (New) The composition of claim 13, wherein the monocytes have been incubated following their treatment by direct contact with a plastic surface.

65. (New) The composition of claim 46, wherein the monocytes have been incubated following their treatment by direct contact with a plastic surface.

As required by 37 C.F.R. §1.121, a copy of the amended claims marked up to show all changes relative to the previous version of these claims is attached to this Amendment.